Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
Phase 2
Active, not recruiting
NCT02893917
| Condition | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | National Cancer Institute (NCI) |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 90 participants |
|---|
| Interventions | Cediranib, Olaparib |
|---|
| Start date | Aug 11, 2017 |
|---|
| Completion date | Mar 14, 2023 |
|---|
| Results posted | Mar 30, 2025 |
|---|
Summary
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving olaparib and cediranib may help treat patients with castration-resistant prostate cancer.
Radiographic Progression Free Survival
Time interval from random assignment to the date when the first site of disease is found to progress, or death, whichever occurs first, assessed up to 5 years · months
| Arm A (Olaparib, Cediranib) | 8.5 months |
|---|
| Arm B (Olaparib) | 4.0 months |
|---|
| p-value | 0.0359 |
|---|
| Hazard Ratio (HR) | 0.617 (95% CI 0.392–0.969) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.